Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 23, 2025 05:00 ET | Source: InnoCare Pharma

InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus

CLE is the second indication InnoCare is developing for ICP-488, and enrollment for the phase III study of ICP-488 for psoriasis is nearing completion.